Ryan Livingston

After following up twice between ages 17 and 24, investigators discovered a three- to five-fold increase in blood glucose and insulin resistance, predicting a matching increase in heart disease risk.

Patients provided with a Post-Acute Care Hypertension consultation and a method of daily medication reminders presented lower blood pressure on follow-up.

Data suggest that etripamil may be more effective than vagal maneuvers and oral prophylaxis, minimizing emergency department visits.

New research links increased dietary selenium intake to reduced cardiovascular disease risk, highlighting its potential benefits for heart health.

Using the American Heart Association’s Life’s Essential 8 model, researchers indicated that preventative action early in life can reduce chances of developing cardiovascular disease later.

A major factor of type 2 diabetes mellitus, dyslipidemia can potentially be prevented by closely monitoring lipid profiles.

Parent company VivaVision plans to request a type C meeting with the US Food and Drug Administration.

Simple choices like improving diet and increasing exercise can influence a healthy individual’s risk of developing cardiovascular disease.

Researchers indicated an association between the index and 365-day mortality.

The program can indicate the severity of nail psoriasis and allow practitioners to quickly and accurately diagnose patients.

An observational study has indicated a correlation between biologic medications and a lower risk of CVD: more research is needed to determine causality.

A secondary analysis of the data collected by the DASH-Sodium trial indicates that dieting and sodium intake limits are additive in their effects on ASCVD risk.

The model could allow cardiologists to inform and prepare patients before symptoms of hypertrophic cardiomyopathy make themselves known.

The scalability and portability of these ECGs could also allow for a community-based approach to heart healthcare.

Analysis suggests that OCT is more consistently accurate and sensitive than color imaging and fluorescein angiography, the accepted standards for imaging.

Without estrogen, the skin barrier weakens, leading to more severe and symptomatic psoriasis.

The FDA identified no issues with the safety or efficacy of aflibercept 8 mg in any of its already approved dosing regimens or indications.

Anemia can moderate the association between both conditions, increasing the risk of atherosclerotic cardiovascular disease.

Results indicate that FDD should be accounted for when measuring ganglion cell inner plexiform layer (GCIPL) in eyes with glaucoma.

If approved, aflibercept 8 mg would mark the first RVO treatment indicated for up to every 8-week dosing, halving the injection frequency of other anti-VEGF options.

Ustekinumab and its generic biofamailiar SYSA1902 exhibited clinical equivalence in terms of safety, efficacy, pharmacokinetics, and immunogenicity.

The study indicates which biomarkers should be prioritized to predict neovascular AMD and geographic atrophy.

Investigators believe the connection may account for a substantial number of anemia cases in children.

Individuals treated with ezetimibe shortly after myocardial infarction experience an improved prognosis versus those who receive delayed treatment or none at all.

Side effects of baricitinib were well within safety parameters, indicating the drug’s viability as a alopecia treatment for adults.

A first-of-its-kind medication developed by Atsena Therapeutics, ATSN-201 has already received three other FDA designations.

Anemia correction reduced perioperative rates but showed no significant impact on postoperative outcomes, emphasizing the need for prehabilitation strategies.

Acute respiratory infection caused by RSV results in a nearly 3-fold increase in mortality, particularly in those with underlying respiratory conditions.

Despite no direct correlation being identified, this research highlights a potential association between the two conditions.

Investigators examined the safety of the recalled sickle cell disease medication through retrospective analysis of an FDA database.